MedTrace Logo

Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

NCT01341808 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 493

Last updated 2013-03-19

No results posted yet for this study

Summary

The purpose of this study is to measure the immune response in 18-40 year old IBD patients after receiving the hepatitis A vaccine.

Conditions

Interventions

BIOLOGICAL

Epaxal Berna (virosomal hepatitis A vaccine)

standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Suk-Kyun Yang, M.D. · Asan Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-02-28
Completion
2013-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341808 on ClinicalTrials.gov